{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:08Z","timestamp":1786988048202,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejim.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T09:38:54Z","timestamp":1629279534000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["State of the art approach to managing angina and ischemia: tailoring treatment to the evidence"],"prefix":"10.1016","volume":"92","author":[{"given":"A.J.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dechend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-9197","authenticated-orcid":false,"given":"J.","family":"Lopez Sendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-980X","authenticated-orcid":false,"given":"G.","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.08.003_bib0001","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2019.09.013","article-title":"Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey","volume":"70","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.ejim.2021.08.003_bib0002","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.08.003_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejim.2019.12.012","article-title":"The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?","volume":"72","author":"Manolis","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2021.08.003_bib0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","article-title":"Medical treatment of stable angina: A tailored therapeutic approach","volume":"220","author":"Manolis","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2021.08.003_bib0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/clc.22479","article-title":"Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease","volume":"38","author":"Zarifis","year":"2015","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0007","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.21037\/jtd.2018.02.43","article-title":"Puskas JD. Fifty years of coronary artery bypass grafting","volume":"10","author":"Melly","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejim.2021.08.003_bib0008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-8703(82)90486-0","article-title":"Results from coronary angioplasty and implications for the future","volume":"103","author":"Gruentzig","year":"1982","journal-title":"American heart journal"},{"key":"10.1016\/j.ejim.2021.08.003_bib0009","unstructured":"Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. The Online journal of current clinical trials. 1994;Doc No 145:[3987 words; 38 paragraphs]."},{"issue":"1","key":"10.1016\/j.ejim.2021.08.003_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM199201023260102","article-title":"A Comparison of Angioplasty with Medical Therapy in the Treatment of Single-Vessel Coronary Artery Disease","volume":"326","author":"Parisi","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"9076","key":"10.1016\/j.ejim.2021.08.003_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(97)07298-X","article-title":"Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants","volume":"350","year":"1997","journal-title":"Lancet"},{"issue":"10022","key":"10.1016\/j.ejim.2021.08.003_bib0012","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejim.2021.08.003_bib0013","first-page":"1119","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"CANTOS Trial Group"},{"key":"10.1016\/j.ejim.2021.08.003_bib0014","doi-asserted-by":"crossref","first-page":"j4","DOI":"10.1136\/bmj.j4","article-title":"Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials","volume":"356","author":"Bangalore","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ejim.2021.08.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012356","article-title":"Preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials","volume":"8","author":"Giugliano","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.ejim.2021.08.003_bib0016","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2018.08.2163","article-title":"Healthy behavior, risk factor control, and survival in the COURAGE Trial","volume":"72","author":"Maron","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.ejim.2021.08.003_bib0017","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.114.013042","volume":"131","author":"Iqbal","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ejim.2021.08.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005455","article-title":"Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program","volume":"12","author":"Xie","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"15","key":"10.1016\/j.ejim.2021.08.003_bib0019","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal Medical Therapy with or without PCI for Stable Coronary Disease","volume":"356","author":"Boden","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.ejim.2021.08.003_bib0020","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease","volume":"360","author":"2D Study Group","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.ejim.2021.08.003_bib0021","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1205361","article-title":"Fractional Flow Reserve\u2013Guided PCI versus Medical Therapy in Stable Coronary Disease","volume":"367","author":"De Bruyne","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.ejim.2021.08.003_bib0022","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial Invasive or Conservative Strategy for Stable Coronary Disease","volume":"382","author":"Maron","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"9744","key":"10.1016\/j.ejim.2021.08.003_bib0023","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejim.2021.08.003_bib0024","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","article-title":"\u03b2-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease","volume":"64","author":"Andersson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ejim.2021.08.003_bib0026","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/eurheartj\/ehy811","article-title":"\u03b2-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study","volume":"40","author":"Sorbets","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ejim.2021.08.003_bib0027","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"issue":"22","key":"10.1016\/j.ejim.2021.08.003_bib0028","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.ejim.2021.08.003_bib0029","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1093\/eurheartj\/ehaa436","article-title":"Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!","volume":"41","author":"Harari","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.003_bib0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.eurheartj.a014699","article-title":"Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group","volume":"17","author":"Fox","year":"1996","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.003_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9149(94)90721-8","article-title":"Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris","volume":"73","author":"Wallace","year":"1994","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0032","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1741826711409325","article-title":"Long-term beta blockers for stable angina: systematic review and meta-analysis","volume":"19","author":"Shu","year":"2012","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2021.08.003_bib0033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fca.14.51","article-title":"Vasodilator \u03b2-blockers: a different class of antihypertensive agents?","volume":"10","author":"Kallistratos","year":"2014","journal-title":"Future Cardiol"},{"issue":"19","key":"10.1016\/j.ejim.2021.08.003_bib0034","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: A scientific statement from the american heart association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.08.003_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0140-6736(02)46032-1","article-title":"Nitroglycerine as a remedy for angina pectoris","volume":"1","author":"Murrell","year":"1879","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1358\/dot.2008.44.3.1193864","article-title":"Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases","volume":"44","author":"Tardif","year":"2008","journal-title":"Drugs Today (Barc)"},{"issue":"23","key":"10.1016\/j.ejim.2021.08.003_bib0037","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.003_bib0038","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"issue":"9641","key":"10.1016\/j.ejim.2021.08.003_bib0039","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.003_bib0040","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1016\/j.ahj.2013.06.024","volume":"166","author":"Fox","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2021.08.003_bib0041","author":"European Medicines","year":"2014","journal-title":"Pharmacovigilance Risk Assessment Committee: (PRAC)"},{"key":"10.1016\/j.ejim.2021.08.003_bib0042","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pharmthera.2008.06.001","article-title":"Pathophysiology and pharmacology of the cardiac \"late sodium current","volume":"119","author":"Zaza","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejim.2021.08.003_bib0043","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2006.10.074","article-title":"Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans. Evidence of a Free-Radical\u2013Mediated Mechanism","volume":"49","author":"Thomas","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0044","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.ejim.2021.08.003_bib0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2021.08.003_bib0046","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0047","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0048","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0049","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2015.10.180","article-title":"Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR)","volume":"205","author":"Alexopoulos","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0051","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40268-013-0026-4","article-title":"Ranolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with Chronic Angina","volume":"13","author":"Muhlestein","year":"2013","journal-title":"Drugs R D"},{"key":"10.1016\/j.ejim.2021.08.003_bib0052","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.08.003_bib0053","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.ejim.2021.08.003_bib0054","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"10014","key":"10.1016\/j.ejim.2021.08.003_bib0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.003_bib0056","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0003319718780551","article-title":"Trimetazidine in the Prevention of Tissue Ischemic Conditions","volume":"70","author":"Kallistratos","year":"2019","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0057","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0003319714530040","article-title":"Trimetazidine and cardioprotection: facts and perspectives","volume":"66","author":"Tsioufis","year":"2015","journal-title":"Angiology"},{"issue":"10254","key":"10.1016\/j.ejim.2021.08.003_bib0058","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","article-title":"ATPCI investigators. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Ferrari","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.08.003_bib0059","doi-asserted-by":"crossref","unstructured":"IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.The Lancet 359:1269\u20131275. doi:10.1016\/S0140-6736(02)08265-X.","DOI":"10.1016\/S0140-6736(02)08265-X"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0060","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1097\/00005344-199206203-00013","article-title":"Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter,double-blind, randomized studies with stable coronary heart disease patients","volume":"20","author":"D\u00f6ring","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0061","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00878320","article-title":"A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris","volume":"7","author":"Di Somma","year":"1993","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2021.08.003_bib0062","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1016\/S0002-9149(99)00025-9","article-title":"Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina","volume":"83","author":"Rajaratnam","year":"1999","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.ejim.2021.08.003_bib0063","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.08.003_bib0064","unstructured":"C:\/Users\/man\/Downloads\/11 12 15 Sanofi Nicorandil Alert (1).pdf n.d."},{"key":"10.1016\/j.ejim.2021.08.003_bib0065","unstructured":"(NICE) NIfHaCE. Stable angina: management. https:\/\/www.nice.org.uk\/guidance\/cg126 (4\/2016; date last accessed) 2016."},{"issue":"9994","key":"10.1016\/j.ejim.2021.08.003_bib0066","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(15)61283-1","article-title":"Pharmacological and emerging therapies in the treatment of chronic angina","volume":"386","author":"Husted","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2021.08.003_bib0067","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.recesp.2012.03.011","article-title":"Stable angina in Spain and its impact on quality of life. The AVANCE registry","volume":"65","author":"Borr\u00e1s","year":"2012","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"16","key":"10.1016\/j.ejim.2021.08.003_bib0068","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","article-title":"The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study","volume":"169","author":"Beltrame","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2021.08.003_bib0069","article-title":"StaBle Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey","author":"Ambrosio","year":"2018","journal-title":"Angiology"},{"issue":"12","key":"10.1016\/j.ejim.2021.08.003_bib0070","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"issue":"27","key":"10.1016\/j.ejim.2021.08.003_bib0071","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ejim.2021.08.003_bib0072","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5455\/medarh.2019.73.72-75","article-title":"Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease","volume":"73","author":"Zvizdic","year":"2019","journal-title":"Med Arch"},{"key":"10.1016\/j.ejim.2021.08.003_bib0073","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"issue":"38","key":"10.1016\/j.ejim.2021.08.003_bib0074","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Members","year":"2013","journal-title":"Eur. Heart J"},{"issue":"18","key":"10.1016\/j.ejim.2021.08.003_bib0075","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.003_bib0076","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248416644987","article-title":"Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension","volume":"22","author":"Ozy\u0131ld\u0131z","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ejim.2021.08.003_bib0077","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/1074248417698224","article-title":"Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review","volume":"22","author":"Padala","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.ejim.2021.08.003_bib0078","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.003_bib0079","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjcard.2017.11.021","article-title":"Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus","volume":"121","author":"Gilbert","year":"2018","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.003_bib0080","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0081","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","article-title":"Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group","volume":"37","author":"Detry","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ejim.2021.08.003_bib0082","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/cer-2017-0011","article-title":"Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes","volume":"6","author":"Meiszterics","year":"2017","journal-title":"J Comp Eff Res"},{"issue":"9","key":"10.1016\/j.ejim.2021.08.003_bib0083","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pds.4585","article-title":"Effect of European Medicines Agency's restrictions on trimetazidine utilization in Portugal","volume":"27","author":"Pinto","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"19","key":"10.1016\/j.ejim.2021.08.003_bib0084","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz","year":"2016","journal-title":"Eur. Heart J"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005027","article-title":"Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: Impact on microvascular and diastolic function","volume":"6","author":"Shah","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.ejim.2021.08.003_bib0086","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.jacc.2018.09.042","article-title":"Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review","volume":"72","author":"Taqueti","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.003_bib0087","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clpt.2005.05.004","article-title":"Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine","volume":"78","author":"Jerling","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521002697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521002697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T19:36:19Z","timestamp":1765222579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521002697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":87,"alternative-id":["S0953620521002697"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.003","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art approach to managing angina and ischemia: tailoring treatment to the evidence","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}